Feature Article

Non–Clear Cell Renal Cell Carcinoma: Unpacking a Messy Term

Abstract: Non–clear cell renal cell carcinoma (nccRCC) is a heterogeneous category comprising approximately 25% of epithelial renal tumors. Unlike their far more common clear cell counterpart, […]

Letter From the Editor

Letter From the Editor: What Would You Do?

As oncologists, how many times have we had to answer the question, “What would you do?” There is always the temptation to answer it with a […]

Lung Cancer in Focus

The Use of Biomarkers in Advanced, Locally Advanced, and Early-Stage Lung Cancer

H&O How has biomarker testing evolved differently for early-stage vs advanced lung cancer? NF We have good data regarding the use of biomarkers for neoadjuvant therapy […]

Melanoma in Focus

Update on LAG3 and Immunotherapy Combinations in Melanoma

H&O How does the mechanism of action of LAG3-targeted therapies differ from that of other immune checkpoint inhibitors? HT LAG3-targeted therapy unlocks an entirely new pathway […]

Advances in Drug Development

Intrathecal Immunotherapy in Patients Who Have Melanoma With Leptomeningeal Disease

H&O What is the rationale behind the use of immunotherapy for intrathecal treatment of leptomeningeal disease (LMD)? ICG When we talk about treatments before the new […]

CLL

The Development of BTK Degraders for Patients With Relapsed CLL

H&O What are Bruton tyrosine kinase (BTK) degraders, and how do they differ from BTK inhibitors? AD BTK degraders are from a new class of molecules, […]